Impact of scheduling on toxicity and clinical efficacy of doxorubicin: What do we know in the mid-nineties?

European Journal of Cancer Part A

Volumn 32, Issue 10, 1996, Pages 1652-1660

  Bielack, S S ^a   Erttmann, R ^a   Kempf Bielack, B ^a   Winkler, K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN;

CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

EID: 0030248579     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00177-3     Document Type: Review

References (129)

1. 1. Myers CE, Chabner BA. Anthracyclines. In Chabner BA, Collins JM, eds. Cancer Chemotherapy, Principles and Practice. Philadelphia, J.B. Lippincott Company, 1990, 356-381.
2. 2. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphological changes. Cancer Treat Rep 1978, 62, 865-872.
3. 3. Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathological analysis of adriamycin cardiotoxicity. Cancer 1973, 32, 302-314.
4. 4. von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979, 91, 710-717.
5. 5. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 1990, 4, 3076-3086.
6. 6. Olson RD, Boerth RC, Gerber JG, Nies AS. Mechanism of adriamycin cardiotoxicity: evidence for oxidative stress. Life Sci 1981, 29, 1393-1401.
7. 7. Basser RL, Green MD. Strategies for prevention of anthracycline cardiotoxicity. Cancer Treat Rev 1993, 19, 57-77.
8. 8. del Tacca M, Danesi R, Ducci M, Bernardini C, Romanini A. Might adriamycinol contribute to adriamycin-induced cardiotoxicity? Pharmacol Res Commun 1985, 17, 1073-1084.
9. 9. Boucek RJ, Olson RD, Brenner DE, Ogunbumni EM, Inui M, Fleischer S. The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. J Biol Chem 1987, 262, 15851-15856.
10. 10. Cusack BJ, Mushlin PS, Voulelis LP, Li X, Boucek RJ Jr, Olson RD. Daunorubicin-induced cardiac injury in the rabbit: a role for daunorubicinol? Toxicol Appl Pharmacol 1993, 118, 177-185.
11. 11. Cusack BJ, Young SP, Driskell J, Olson RD. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother Pharmacol 1993, 32, 53-58.
12. 12. Benjamin RS, Wiernik PH, Bachur NR. Adriamycin chemotherapy: efficacy, safety, and pharmacological basis of an intermittent single high-dosage schedule. Cancer 1973, 33, 19-27.
13. 13. Gottlieb JA, Lefrak EA, O'Bryan RM, et al. Fatal adriamycin cardiomyopathy: prevention by dose limitation. Proc Annu Meet Am Assoc Cancer Res 1973, 14, 88.
14. 14. von Hoff DD, Layard M. Risk factors for development of daunorubicin cardiotoxicity. Cancer Treat Rep 1981, 65 (Suppl. 4), 19-23.
15. 15. Hausdorf G, Morf G, Beron G, et al. Long term doxorubicin cardiotoxicity in childhood: non-invasive evaluation of the contractile state and diastolic filling. Br Heart J 1988, 60, 309-315.
16. 16. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991, 324, 808-815.
17. 17. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Murphy ML. Cardiotoxicity 4-20 years after completing anthracycline therapy. JAMA 1991, 266, 1672-1677.
18. 18. Geidel S, Garn M, Grävinghoff L, et al. Cardiomyopathy after treatment for osteosarcoma: a contribution to cardiotoxicity of adriamycin. Klin Pädiatr 1991, 203, 257-261.
19. 19. Bu'Lock FA, Mott MG, Oakhill A, Martin RP. Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology. Br Heart J 1995, 73, 340-350.
20. 20. Lang D, Hilger F, Binswanger J, Andelfinger G, Hartmann W. Late effects of anthracycline therapy in childhood in relation to the function of the heart at rest and under physical stress. Eur J Pediatr 1995, 154, 340-345.
21. 21. Druck MN, Gulenchyn KY, Evans WK, et al. Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity. Cancer 1984, 53, 1667-1674.
22. 22. Maione S, Giunta A, Tuccillo B, et al. Doppler echocardiographic assessment of left ventricular function in patients with primary lung cancer treated with doxorubicin. Tumor: 1988, 74, 725-729.
23. 23. Marchandise B, Schroeder E, Bosly A, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989, 118, 92-98.
24. 24. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995, 332, 1738-1743.
25. 25. Gottlieb SL, Edminston WA, Haywood LJ. Late, late doxorubicin cardiotoxicity. Chest 1980, 78, 880-882.
26. 26. Steinherz LJ, Steinherz P. Cardiac failure more than six years post anthracyclines. Am J Cardiol 1988, 62, 505 (Abstract).
27. 27. Goorin AM, Chauvenet AR, Perez-Atayde AR, Cruz J, McKone R, Lipshultz SE. Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr 1990, 116, 144-147.
28. 28. Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Pediat Oncol 1995, 24, 352-361.
29. 29. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children's Cancer Study Group. Pediatrics 1992, 89, 942-949.
30. 30. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992, 19, 670-686.
31. 31. Wexler LH, Berg S, Andrich M, et al. ICRF-187 reduces doxorubicin-induced cardiotoxicity with no impact on response to chemotherapy. Proc Annu Meet Amer Soc Clin Oncol 1993, 29, A1434.
32. 32. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992, 10, 117-127.
33. 33. Herman EH, Rahman A, Ferrans VJ, Vick JA, Schein PS. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res 1983, 43, 5427-5432.
34. 34. Napoli S, Burton MA, Martins IJ, Chen Y, Codde JP, Gray BN. Dose response and toxicity of doxorubicin microspheres in a rat tumor. Anticancer Drugs 1992, 3, 47-53.
35. 35. Weiss AJ, Metter GE, Fletcher WS, et al. Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep 1976, 60, 813-822.
36. 36. Weiss AJ, Manthel RW. Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity. Cancer 1977, 40, 2046-2052.
37. 37. Chlebowski RT, Paroly WS, Pugh RP, et al. Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 1980, 64, 47-51.
38. 38. Gercovich FG, Praga C, Beretta G, et al. Ten-hour continuous infusion of adriamycin. Proc Annu Meet Am Assoc Cancer Res and ASCO 1979, 20, 372 (Abstract).
39. 39. Green MD, Speyer JS, Bottino JC, Blum RH, Wernz JC, Muggia FM. Phase I-II study of the continuous infusion of doxorubicin in the treatment of non-small cell lung cancer. Cancer Treat Rep 1984, 68, 681-682.
40. 40. Shapiro J, Gotfried M, Lishner M, Ravid M. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation. Cancer 1990, 65, 870-873.
41. 41. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982, 96, 133-139.
42. 42. Hortobagyi GN, Frye D, Buzdar AU, et al. Decreased cardiac toxicity of doxorubicin administered by continuous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 1989, 63, 37-45.
43. 43. Lokich J, Bothe T, Zipoli R, et al. Constant infusion schedule for adriamycin. A phase I-II clinical trial of a 30-day schedule by ambulatory pump delivery system. J Clin Oncol 1983, 1, 24-28.
44. 44. Garnick MB, Weiss GR, Steele GD, et al. Clinical evaluation of long term, continuous-infusion doxorubicin. Cancer Treat Rep 1983, 67, 133-142.
45. 45. Jain K, Wines R, Benedetto P, et al. A randomized comparison of weekly (Arm I) Vs. monthly (Arm II) doxorubicin (DOX) in combination with mitomycin C (MMC) in advanced breast cancer. Proc Annu Meet Am Soc Clin Oncol 1983, 2, 109 (Abstract).
46. 46. Torti FM, Bristow MR, Howes AE, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Ann Intern Med 1983, 99, 745-749.
47. 47. Chlebowski RT, Bull F, Irwin L, Pugh R, Weiner JM, Bateman JR. Doxorubicin and methotrexate on a weekly schedule in patients with sarcomas. Oncology 1987, 44, 210-213.
48. 48. Valdivieso M, Burgess MA, Ewer MS, et al. Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study. J Clin Oncol 1984, 2, 207-214.
49. 49. Umsawadi T, Valdivieso M, Booser DJ, et al. Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer. Cancer 1989, 64, 1995-2000.
50. 50. Legha SS, Benjamin RS, Mackay B, et al. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer 1982, 49, 1762-1766.
51. 51. Legha SS, Benjamin RS, Ewer M, et al. Continuous intravenous infusion of adriamycin: evaluation of its efficacy and toxicity. Excerpta Med Int Congr Ser 1984, 629, 378-386.
52. 52. Zalupski M, Metch B, Balcerzak S, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst 1991, 83, 926-932.
53. 53. Speyer JL, Bottino J, Nidus B, et al. Adriamycin (ADM) 24 hour infusion: a phase I trial. Proc Annu Meet Am Assoc Cancer Res and ASCO 1981, 22, 363 (Abstract).
54. 54. Neglia JP, Woods WG. Continuous-infusion doxorubicin in the treatment of primary hepatic malignancies of childhood. Cancer Treat Rep 1986, 70, 655-657.
55. 55. Savage PD, Skubitz KM. Continuous infusion chemotherapy for soft tissue sarcomas. Proc Annu Meet Am Soc Clin Oncol 1989, 8, A1249.
56. 56. Casper ES, Gaynor JJ, Hajdu SI, et al. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer 1991, 68, 1221-1229.
57. 57. Jasmin C, Gil-Delgado MA, Marino JP, Ecstein E, Descorps-Declere A, Misset JL. Phase I-II constant infusion of adriamycin (doxorubicin) by ambulatory pump delivery system in heavily pretreated (including adriamycin) breast cancer patients. Ann Oncol 1990, 1, 189-193.
58. 58. Vogelzang NJ, Ruane M, DeMeester TR. Phase I trial of an implanted battery-powered, programmable drug delivery system for continuous doxorubicin administration. J Clin Oncol 1985, 3, 407-414.
59. 59. Samuels BL, Vogelzang NJ, Ruane M, Simon MA. Continuous venous infusion of doxorubicin in advanced sarcomas. Cancer Treat Rep 1987, 71, 971-972.
60. 60. Bode U, Schmalenbach U. Doxorubicin Dauerinfusionen. Eine Pilotstudie bei jugendlichen Patienten. Klin Pädiatr 1988, 200, 271-273.
61. 61. DelaFlor-Weiss E, Uziely B, Muggia FM. Protracted drug infusions in cancer treatment: an appraisal of 5-fluorouracil, doxorubicin, and platinums. Ann Oncol 1993, 4, 723-733.
62. 62. de Valeriola D. Dose optimization of anthracyclines. Anticancer Res 1994, 14, 2307-2314.
63. 63. Sweatman TW, Lokich JL, Israel M. Clinical pharmacology of continuous infusion doxorubicin. Ther Drug Monit 1989, 11, 3-9.
64. 64. Boston RC, Phillips DR. Evidence of possible dose-dependent doxorubicin plasma kinetics in man. Cancer Treat Rep 1983, 67, 63-69.
65. 65. Robert J, Bui NB, Vrignaud P. Pharmacokinetics of doxorubicin in sarcoma patients. Eur J Clin Pharmacol 1987, 31, 695-699.
66. 66. Eksborg S, Strandler HS, Edsmyr F, Näslund I, Tahvanainen P. Pharmacokinetic study of IV infusions of adriamycin. Eur J Clin Pharmacol 1985, 28, 205-212.
67. 67. Erttmann R, Erb N, Steinhoff A, Landbeck G. Pharmacokinetics of doxorubicin in man: dose and schedule dependence. J Cancer Res Clin Oncol 1988, 114, 509-513.
68. 68. Bronchud MH, Margison RF, Howell A, Lind M, Lucas SB, Wilkinson PM. Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer. Cancer Chemother Pharmacol 1990, 25, 435-439.
69. 69. Frenay M, Milano G, Renee N, et al. Pharmacokinetics of weekly low dose doxorubicin. Eur J Cancer Clin Oncol 1989, 25, 191-195.
70. 70. Bielack SS, Erttmann R, Winkler K, Landbeck G. Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy. Eur J Cancer Clin Oncol 1989, 25, 873-882.
71. 71. Rossi C, Gasparini G, Canobbio L, et al. Doxorubicin distribution in human breast cancer. Cancer Treat Rep 1987, 71, 1221-1226.
72. 72. Twelves CJ, Dobbs NA, Aldhous M, Harper PG, Rubens RD, Richards MA. Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer. Cancer Chemother Pharmacol 1991, 28, 302-307.
73. 73. Speth PA, Linssen PCM, Boezemann JBM, Wessels HMC, Haanen C. Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients. Cancer Chemother Pharmacol 1987, 20, 305-310.
74. 74. Speth PA, Linssen PCM, Holdrinet RGS, Haanen C. Plasma and cellular adriamycin concentrations in patients with myeloma treated with ninety-six-hour continuous infusion. Clin Pharmacol Ther 1987, 41, 661-665.
75. 75. Muller C, Chatelut E, Gualano V, et al. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. Cancer Chemother Pharmacol 1993, 32, 379-384.
76. 76. Raijmakers R, Speth P, de Witte T, Linssen P, Wessels J, Haanen C. Infusion-rate independent cellular adriamycin concentrations and cytotoxicity to human bone marrow clonogenic cells (CFU-GM). Br J Cancer 1987, 56, 123-126.
77. 77. Legha SS, Benjamin RS, Yap HY. Augmentation of adriamycin's therapeutic index by prolonged continuous I.V. infusion for advanced breast cancer. Proc Annu Meet Am Assoc Cancer Res 1979, 20, 261 (Abstract).
78. 78. Ackland SP, Ratain MJ, Vogelzang NJ, Choi KE, Ruane M, Sinkule SA. Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin. Clin Pharmacol Ther 1989, 45, 340-347.
79. 79. Storm G, van Hoesel QGCM, de Groot G, Kop W, Steerenberg PA, Hillen FC. A comparative study on the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus, continuous infusion or entrapped in liposomes in the lou/M Ws1 rat. Cancer Chemother Pharmacol 1989, 24, 341-348.
80. 80. Brenner DE, Grosh WW, Noone R, Stein R, Greco FA, Hande KR. Human plasma pharmacokinetics of doxorubicin: comparison of bolus and infusional administration. Cancer Treat Symp 1984, 3, 77-83.
81. 81. Paul C, Tidefeld U, Liliemark J, Peterson C. Increasing the accumulation of daunorubicin in human leukaemia cells by prolonging the infusion time. Leukemia Res 1989, 13, 191-196.
82. 82. Timour Q, Nony P, Lang J, Lakhal M, Trllet V, Faucon G. Doxorubicin concentration time course in the myocardium after single administration to the dog. Cancer Chemother Pharmacol 1987, 20, 267-269.
83. 83. Robert J. Continuous infusion or intravenous bolus: what is the rationale for doxorubicin administration? Cancer Drug Deliv 1987, 4, 191-199.
84. 84. Eichholtz-Wirth H. Dependence of the cytostatic effect of adriamycin on drug concentration and exposure time in vitro. Br J Cancer 1980, 41, 886-891.
85. 85. Carmichael J, de Graff WG, Gazdar A, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semi-automated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987, 47, 936-942.
86. 86. Mergenthaler HG, Bruhl P, Ehninger G, Heidemann E. Comparative in vitro toxicity of mitoxantrone and adriamycin in human granulocyte-macrophage progenitor cells. Cancer Chemother Pharmacol 1987, 20, 8-12.
87. 87. Yang KP, Famaan NA. Lethal efficacy of doxorubicin on human medullary thyroid carcinoma cells in vitro. Anticancer Res 1988, 8, 245-248.
88. 88. Andersson B, Beran M, Peterson C, Tribukait B. Significance of cellular pharmacokinetics for the cytotoxic effects of daunorubicin. Cancer Res 1982, 42, 178-183.
89. 89. Nguyen-Ngoc T, Vrignaud P, Robert J. Cellular pharmacokinetics of doxorubicin in cultured mouse sarcoma cells originating from autochtonous tumors. Oncology 1984, 41, 55-60.
90. 90. Vrignaud P, Londos-Gagliardi D, Robert J. Cellular pharmacology of doxorubicin in sensitive and resistant rat glioblastoma cells in culture. Oncology 1986, 43, 60-66.
91. GM at plasma concentrations found following therapeutic infusions. Br J Cancer 1984, 50, 351-355.
92. 92. Buick RN, Messner HA, Till JE, McCulloch EA. Cytotoxicity of adriamycin and daunorubicin for normal and leukemia progenitor cells of man. J Natl Cancer Inst 1979, 62, 249-255.
93. 93. Ritch PS, Occhipinti SJ, Skramstad KS, et al. Increased relative effectiveness of doxorubicin against slowly proliferating sarcoma 180 cells after prolonged drug exposure. Cancer Treat Rep 1982, 66, 1159-1168.
94. 94. Milano G, Cassuto Viguier E, Fischel JL, et al. Doxorubicin weekly low dose administration: in vitro cytoxicity generated by the typical pharmacokinetic profile. Eur J Cancer 1992, 28A, 1881-1885.
95. 95. Hu XF, Slater A, Wall DM, et al. Rapid up-regulation of mdrl expression by anthracyclines in a classical multidrug-resistant cell line. Br J Cancer 1995, 71, 931-936.
96. 96. Chevillard S, Vielh P, Bastian B, Coppey J. A single 24h contact time with adriamycin provokes the emergence of resistant cells expressing the gp 170 protein. Anticancer Res 1992, 12, 495-500.
97. 97. Lai GM, Chen YN, Mickley LA, Fojo AT, Bates SE. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 1991, 49, 696-703.
98. 98. Anderson N, Lokich JJ. Cancer chemotherapy and infusional scheduling. Oncology Huntingt 1994, 8, 99-111.
99. 99. Borden EC, Amato DA, Rosenbaum CH, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987, 5, 840-850.
100. 100. Bielack SS, Fuchs N, Bieling P, et al. Effect of doxorubicin (DOX) schedule on tumor response and survival in osteosarcoma (OS). Results of sequential trials COSS 86A-C. Med Pediatr Oncol 1994, 23, 176 (Abstract).
101. 101. Lokich JA, Auerbach M, Smith MA, et al. A comparative trial of three schedules for single-agent doxorubicin in advanced breast cancer. An aborted investigation. J Infus Chemo 1992, 2, 185-188.
102. 102. Richards MA, Hopwood P, Ramirez AJ, et al. Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life. Eur J Cancer 1992, 28A, 1023-1028.
103. 103. Gundersen S, Kvinnsland S, Klepp O, Kvaloy S, Lund E, Host O. Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial. Eur J Cancer Clin Oncol 1986, 22, 1431-1434.
104. 104. Anderson H, Hopwood P, Prendiville J, Radford JA, Thatcher N, Ashcroft L. A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer. Br J Cancer 1993, 67, 1385-1390.
105. 105. Souhami RL, Rudd R, Ruiz de Elvira MC, et al. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial. J Clin Oncol 1994, 12, 1806-1813.
106. 106. Sculier JP, Paesmans M, Bureau G, et al. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. J Clin Oncol 1993, 11, 1858-1865.
107. 107. Casper E, Magill G, Freidrich C, Gaynor J, Hajdu S, Brennan M. Prospective randomized trial of adjuvant adriamycin (A) by bolus (B) vs 72-hour continuous infusion (CI) in patients (PTS) with high grade soft tissue sarcoma (HGS). Proc Annu Meet Am Soc Clin Oncol 1989, 8, A1246.
108. 108. Tierney JF, Mosseri V, Stewart LA, Souhami RL, Parmar MKB. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials. Br J Cancer 1995, 72, 469-475.
109. 109. Bieling P, Winkler K, Bielack S, et al. Continuous infusion (CI) versus short term infusion (SI) of doxorubicin (DOX) in osteosarcoma. Proc Annu Meet Am Soc Clin Oncol 1991, 10, 308A.
110. 110. Smith MA, Ungerleider RS, Horowitz ME, Simon R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 1991, 83, 1460-1470.
111. 111. Benjamin RS, Chawla SP, Carrasco CH, et al. Preoperative chemotherapy for osteosarcoma with intravenous adriamycin and intra-arterial cisplatinum. Ann Oncol 1992, 3, 3-6.
112. 112. Blomqvist C, Elooma I, Rissanen P, Hietanen P, Nevasaari K, Helle L. Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer. A randomized trial comparing weekly and every-4-week administration. J Clin Oncol 1993, 11, 467-473.
113. 113. Twelves CJ, Ramirez AJ, Richards MA, et al. A comparison of response, survival and quality of life (QOL) using 2 doxorubicin schedules of equal dose intensity in metastatic breast cancer. Br J Cancer 1990, 62, 498-499.
114. 114. Anderson H, Prendiville J, Thatcher N, Radford JA, Swindell R. A randomised study of intravenous bolus vs continuous infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer. J Cancer Res Clin Oncol 1991, 117 (Suppl. IV), S139-S140.
115. 115. Preisler HD, Gessner T, Azarnia N, et al. Relationship between plasma adriamycin level and the outcome of remission induction therapy for acute non-lymphocytic leukemia. Cancer Chemother Pharmacol 1984, 12, 125-130.
116. 116. Donohue SM, Boughton BJ. Fractionated anthracycline therapy in acute myeloblastic leukemia in adults. Cancer Chemother Pharmacol 1989, 23, 401-402.
117. 117. Archimbaud E, Anglaret B, Thomas X, et al. Continuous-infusion daunorubicin and carboplatin for high-risk acute myeloid leukemia in the elderly. Leukemia 1992, 6, 776-779.
118. 118. Friedenberg WR, Miller HJ, Marx JJ, et al. The treatment of older adult patients with acute myeloid leukemia by triple infusion chemotherapy. Am J Clin Oncol 1995, 18, 105-110.
119. 119. Lewis JP, Meyers FJ, Tanaken L. Daunomycin administered by continuous infusion is effective in the treatment of acute non-lymphocytic leukemia. Br J Haematol 1985, 61, 261-265.
120. 120. Janka GE, Harms D, Schwamborn D, et al. Daunorubicin-induced cell kill with 1-hour vs. 24-hour infusions: randomized comparison in newly diagnosed children with acute lymphoblastic leukemia. Proceedings of the XIIth Meeting of the International Society of Hematology. Vienna, 28 August-3 September 1993.
121. 121. Steinherz PG, Redner A, Steinherz L, Meyers P, Tan C, Heller G. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol. Cancer 1993, 72, 3120-3130.
122. 122. Shaw PJ, Eden T, Paradisis M. Induction toxicity in acute lymphoblastic leukemia: a comparison of two schedules of daunorubicin administration. Med Pediatr Oncol 1995, 24, 18-22.
123. 123. Sparano JA, Wiernik PH, Leaf A, Dutcher JP. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy. J Clin Oncol 1993, 11, 1071-1079.
124. 124. Carrion JR, Garcia-Arroyo FR, Saunas P. Infusional chemotherapy (EPOCH) in patients with refractory or relapsed lymphoma. Am J Clin Oncol 1995, 18, 44-16.
125. 125. Slevin ML, Clark PL, Joel SP, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 1989, 7, 1333-1339.
126. 126. Anderson H, Scarffe JH, Ranson M, et al. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer 1995, 71, 326-330.
127. 127. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984, 310, 1353-1356.
128. 128. Browman GP, Belch A, Shillings J, Wilson K, Bergsagel D. Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. Br J Haematol 1992, 82, 555-559.
129. 129. Koskela K, Pelliniemi TT, Remes K. VAD regimen in the treatment of resistant multiple myeloma: slow or fast infusion? Leuk Lymphoma 1993, 10, 347-351.